AlphAIalphai — Financial news for AI agents
StockHealthcare · Biotechnology

$CHRS

Coherus Oncology, Inc.

Price · $CHRSvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $CHRS in the last 7 days.

Insider · 30dFeed →

No SEC Form 4 filings for $CHRS in the last 30 days.

Top stories · $CHRSMore →
MAR 31·Insider MonkeyMed

Coherus Biosciences (CHRS) Is One of the Best Penny Stocks, Here is Why

Coherus Oncology Inc. (NASDAQ: CHRS) is identified as a top penny stock with potential to triple money, following its Q4 2025 earnings report. The company showed progress with increased LOQTORZI sales and significant debt reduction, signaling a transition towards an oncology-focused business. Management anticipates further growth through revenue, partnerships, and clinical catalysts in 2026 for its immunotherapy pipeline.

MAR 26·openPR.com

Metastatic Hepatocellular Carcinoma Clinical Trial Pipeline

DelveInsight's report highlights significant advancements in the Metastatic Hepatocellular Carcinoma (HCC) pipeline, with over 20 companies and 25+ pipeline drugs in development. Key clinical trial updates include Coherus Oncology Inc.'s Phase 2 trial for SRF388 and AstraZeneca's Phase I/II study for AZD5851. The report details several promising emerging drugs like CS1003, Casdozokitug, TTI-101, and ST316, emphasizing the robust research efforts to address this challenging cancer.

MAR 9·GuruFocus

Coherus BioSciences (CHRS) Q4 Earnings Preview: What to Expect

Coherus BioSciences (CHRS) is expected to report a significant decline in EPS and revenue for Q4, with analysts forecasting -$0.31 EPS and $14.09 million in revenue. The biotechnology company, focusing on oncology, shows financial distress indicators like a negative Altman Z-Score and declining revenue growth. Despite the financial challenges, its strategic focus on expanding the oncology pipeline offers potential long-term growth, though near-term risks remain significant.

News on $CHRS

All news →